Drugs Affecting Blood and Blood Formation Practice Questions

Q: What is the latest oral direct thrombin inhibitor?

Dabigatran. ### Explanation **Correct Answer: C. Dabigatran** **Mechanism and Rationale:** Dabigatran etexilate is a potent, competitive, and reversible **Direct Thrombin Inhibitor (DTI)**. Unlike heparin, which acts indirectly via antithrombin III, DTIs bind directly to the active site of both free and clot-bound thrombin (Factor IIa). It is administered as a prodrug and is currently the only orally available DTI approved for clinical use (e.g., for stroke prevention in atrial fibrillation and DVT prophylaxis). **Analysis of Incorrect Options:** * **A. Ximelagatran:** This was the first oral DTI developed. However, it was withdrawn from the market worldwide due to significant **hepatotoxicity** (elevation of liver enzymes). Dabigatran is the "latest" successful successor in this class. * **B. Idraparinux:** This is a long-acting synthetic polysaccharide that acts as an indirect **Factor Xa inhibitor**. It is administered subcutaneously, not orally. * **D. Fondaparinux:** This is a synthetic pentasaccharide that selectively inhibits **Factor Xa** by binding to antithrombin III. It is administered via subcutaneous injection and is not a thrombin inhibitor. **High-Yield Clinical Pearls for NEET-PG:** * **Reversal Agent:** The specific monoclonal antibody fragment used to reverse Dabigatran is **Idarucizumab** (Praxbind). * **Monitoring:** Unlike Warfarin, Dabigatran does not require routine INR monitoring. However, in emergencies, the **Diluted Thrombin Time (dTT)** or Ecarin Clotting Time (ECT) are the most sensitive tests. * **Excretion:** It is primarily eliminated by the **kidneys** (80%), so it must be used with caution or avoided in severe renal impairment. * **Comparison:** Remember the "Gatrans" (Dabigatran) are Thrombin (IIa) inhibitors, while the "Xabans" (Rivaroxaban, Apixaban) are Factor Xa inhibitors.

Q: Which of the following antiplatelet drugs is a P2Y12 receptor blocker not affected by CYP2C19 polymorphism?

Prasugrel. **Explanation:** The correct answer is **Prasugrel**. **1. Why Prasugrel is correct:** Prasugrel is a third-generation thienopyridine P2Y12 receptor antagonist. Like clopidogrel, it is a prodrug; however, its metabolic activation is more efficient. It is rapidly hydrolyzed by esterases and then converted to its active metabolite by various CYP enzymes (primarily **CYP3A4 and CYP2B6**). Crucially, its activation is **not significantly dependent on CYP2C19**. Therefore, its antiplatelet efficacy is not affected by the genetic polymorphisms of CYP2C19 (poor metabolizers), leading to a more predictable and potent antiplatelet response compared to clopidogrel. **2. Why the other options are incorrect:** * **Clopidogrel:** This is a second-generation thienopyridine that relies heavily on a two-step hepatic activation process where **CYP2C19** plays a major role. Patients with a loss-of-function CYP2C19 allele are "poor metabolizers" and face a higher risk of cardiovascular events due to reduced active drug levels. * **Eptifibatide:** This is a **GP IIb/IIIa inhibitor**, not a P2Y12 blocker. It is administered intravenously and acts by preventing fibrinogen binding to platelets. * **Dipyridamole:** This drug acts primarily as a **phosphodiesterase (PDE) inhibitor**, increasing cAMP levels in platelets. It does not act on the P2Y12 receptor. **High-Yield Clinical Pearls for NEET-PG:** * **Ticagrelor** is another P2Y12 blocker not affected by CYP2C19 because it is **direct-acting** (not a prodrug) and binds reversibly. * **Prasugrel Contraindication:** It is strictly contraindicated in patients with a **prior history of stroke or TIA** due to a significantly increased risk of intracranial hemorrhage. * **Drug Interaction:** Avoid using **Omeprazole** (a CYP2C19 inhibitor) with Clopidogrel, as it reduces the antiplatelet effect. Pantoprazole is a safer alternative.

Q: Ferrous sulfate is a hydrated salt containing what percentage of Iron?

20%. **Explanation:** The correct answer is **20% (Option A)**. In pharmacology, it is crucial to distinguish between the total weight of an iron salt and its **elemental iron** content, as the latter determines the therapeutic efficacy and potential toxicity. **1. Why 20% is correct:** Ferrous sulfate is commonly administered as the hydrated salt ($FeSO_4 \cdot 7H_2O$) or the dried salt. The standard hydrated form contains approximately **20% elemental iron** by weight. For example, a standard 300 mg tablet of ferrous sulfate provides roughly 60 mg of elemental iron ($300 \times 0.20 = 60$). This is the "gold standard" for oral iron therapy due to its high bioavailability and low cost. **2. Why other options are incorrect:** * **Options B, C, and D:** These percentages do not correspond to Ferrous sulfate. However, they may be confused with other iron salts. For instance, **Ferrous fumarate** contains about **33%** elemental iron (closest to Option C/D), while **Ferrous gluconate** contains only **12%**. **High-Yield Clinical Pearls for NEET-PG:** * **Elemental Iron Content:** Remember the "Rule of Iron Salts": * Ferrous Gluconate: 12% * Ferrous Sulfate: 20% * Ferrous Fumarate: 33% (Highest among common oral salts). * **Absorption:** Oral iron is best absorbed in the **ferrous ($Fe^{2+}$)** state and in an **acidic medium**. Vitamin C (Ascorbic acid) enhances absorption, while antacids, tea, and tetracyclines inhibit it. * **Side Effects:** Epigastric pain, constipation, and black stools (must be differentiated from melena). * **Treatment Duration:** In Iron Deficiency Anemia, treatment should continue for **3–6 months** after hemoglobin normalizes to replenish depleted iron stores (ferritin).

Q: What is the mode of action of warfarin?

Vitamin K antagonist. **Explanation:** **Mechanism of Action:** Warfarin is a **Vitamin K Antagonist (VKA)**. It acts by inhibiting the enzyme **Vitamin K Epoxide Reductase (VKORC1)**. This enzyme is responsible for converting inactive vitamin K epoxide back into its active form (hydroquinone). Active vitamin K is a necessary cofactor for the **gamma-carboxylation** of glutamate residues on certain clotting factors. Without this post-translational modification, **Factors II, VII, IX, and X**, as well as **Proteins C and S**, remain inactive (PIVKA—Proteins Induced by Vitamin K Absence). **Analysis of Incorrect Options:** * **Option A (Factor Xa inhibitor):** This describes the mechanism of Direct Oral Anticoagulants (DOACs) like **Rivaroxaban** and **Apixaban**, or indirect inhibitors like Fondaparinux. * **Option C (Activates antithrombin III):** This is the mechanism of **Heparin** and Low Molecular Weight Heparins (LMWH). They bind to antithrombin III, accelerating its inactivation of Thrombin (IIa) and Factor Xa. * **Option D (Activates factor IX):** This is incorrect; anticoagulants aim to inhibit, not activate, clotting factors. **NEET-PG High-Yield Pearls:** * **Monitoring:** Warfarin therapy is monitored using **PT/INR** (Prothrombin Time/International Normalized Ratio). * **Teratogenicity:** Warfarin is contraindicated in pregnancy (causes **Fetal Warfarin Syndrome**—chondrodysplasia punctata); LMWH is the drug of choice. * **Skin Necrosis:** Occurs due to the rapid depletion of Protein C (short half-life) causing a transient hypercoagulable state. This is why "Heparin bridging" is required. * **Antidote:** For immediate reversal, use **Fresh Frozen Plasma (FFP)** or Prothrombin Complex Concentrate (PCC). For non-emergency reversal, use **Vitamin K1 (Phytonadione)**.

Q: Low molecular weight heparin therapy is associated with all of the following except:

High biological interaction to plasma proteins. ### Explanation The correct answer is **D. High biological interaction to plasma proteins.** Low Molecular Weight Heparins (LMWHs), such as Enoxaparin and Dalteparin, are derived from Unfractionated Heparin (UFH) through depolymerization. This process significantly alters their pharmacokinetic profile. **1. Why Option D is the correct (incorrect statement):** Unlike UFH, LMWHs have **low affinity for plasma proteins**, vascular endothelial cells, and macrophages. This lack of protein binding results in a highly **predictable dose-response relationship**, eliminating the need for routine laboratory monitoring (like aPTT). UFH, conversely, binds extensively to plasma proteins, leading to variable bioavailability. **2. Analysis of Incorrect Options:** * **A. Less chances of bleeding:** LMWHs have a higher ratio of Anti-Xa to Anti-IIa activity. They do not inhibit thrombin as strongly as UFH and have less effect on platelet function and vascular permeability, leading to a lower risk of major bleeding and Heparin-Induced Thrombocytopenia (HIT). * **B. Single dose per day:** LMWHs have a longer half-life (3–6 hours) compared to UFH (1–2 hours) and better subcutaneous bioavailability. This allows for convenient once or twice-daily dosing. * **C. Easy filterability by glomerular capillaries:** Due to their smaller molecular size (~5000 Da), LMWHs are primarily excreted by the kidneys. This makes them "easily filterable" but also necessitates dose adjustment or avoidance in patients with renal failure (CrCl <30 ml/min). **Clinical Pearls for NEET-PG:** * **Monitoring:** While UFH is monitored by **aPTT**, LMWH monitoring (if required, e.g., in pregnancy or obesity) is done via **Factor Xa assay**. * **Antidote:** Protamine sulfate completely neutralizes UFH but only **partially** neutralizes LMWH. * **Drug of Choice:** LMWH is the preferred anticoagulant in **pregnancy** as it does not cross the placenta.

Q: Warfarin therapy during the first trimester of pregnancy can lead to which of the following problems?

Chondrodysplasia punctata. **Explanation:** Warfarin is a low-molecular-weight anticoagulant that readily crosses the placenta. When administered during the **first trimester** (specifically between **6 to 9 weeks** of gestation), it interferes with the carboxylation of osteocalcin and other bone proteins, leading to a specific constellation of defects known as **Fetal Warfarin Syndrome (Warfarin Embryopathy).** **1. Why Chondrodysplasia Punctata is Correct:** The hallmark of Warfarin Embryopathy is **Chondrodysplasia punctata**, characterized by "stippled epiphyses" (calcific punctations) visible on X-ray. This occurs due to the inhibition of Vitamin K-dependent clotting factors and bone proteins during the critical period of organogenesis. Other features include **nasal hypoplasia** (depressed nasal bridge) and midface hypoplasia. **2. Why Incorrect Options are Wrong:** * **Fetal Optic Atrophy & Mental Retardation:** While these CNS abnormalities can occur with Warfarin use, they are typically associated with exposure during the **second and third trimesters**. CNS damage is usually the result of micro-hemorrhages in fetal neural tissue rather than the primary teratogenic effect seen in the first trimester. Since the question specifically asks for first-trimester problems, Chondrodysplasia punctata is the most specific and classic answer. **High-Yield Clinical Pearls for NEET-PG:** * **Critical Period:** 6–9 weeks of gestation. * **Safe Alternative:** **Heparin** (Unfractionated or LMWH) is the drug of choice in pregnancy because it is a large molecule and **does not cross the placenta**. * **Warfarin in Late Pregnancy:** Use near term can cause fetal/neonatal hemorrhage and placental abruption due to the trauma of labor. * **Breastfeeding:** Warfarin is **safe** during breastfeeding as it is not excreted in breast milk.

Q: Which of the following statements about erythropoietin is FALSE?

It results in a decrease in reticulocyte count. ### Explanation **Why Option B is the Correct (False) Statement:** Erythropoietin (EPO) is a glycoprotein hormone that stimulates the proliferation and differentiation of red blood cell precursors in the bone marrow. When administered, it triggers the release of immature red blood cells, known as **reticulocytes**, into the bloodstream. Therefore, a successful response to EPO therapy is characterized by an **increase in reticulocyte count** (usually within 7–10 days), not a decrease. A rising reticulocyte count is the earliest indicator of the drug's efficacy. **Analysis of Incorrect Options:** * **Option A:** Chronic Renal Failure (CRF) leads to a deficiency of endogenous erythropoietin because the peritubular interstitial cells of the kidney are damaged. Recombinant human erythropoietin (Epoetin alfa) is the **standard of care** for anemia in CRF. * **Option C:** By stimulating the body’s own production of RBCs, EPO increases hemoglobin levels, thereby significantly **reducing the need for repeated blood transfusions** and minimizing risks like iron overload or transfusion-transmitted infections. * **Option D:** **Hypertension** is the most common and serious side effect of EPO therapy. It is thought to occur due to a rapid increase in red cell mass and peripheral vascular resistance. **NEET-PG High-Yield Pearls:** * **Target Hemoglobin:** In CRF patients, EPO should be titrated to maintain Hb between **10–12 g/dL**. Exceeding 12 g/dL increases the risk of stroke and cardiovascular events. * **Iron Stores:** EPO therapy is ineffective if iron stores are low. Always check **ferritin levels** before starting treatment. * **Darbepoetin alfa:** A long-acting glycosylated form of EPO with a half-life 3 times longer than Epoetin alfa. * **Other Uses:** Anemia due to Zidovudine (in HIV), chemotherapy-induced anemia, and preoperative autologous blood donation.

Q: All of the following are parenteral Direct Thrombin Inhibitors except?

Dabigatran. **Explanation:** Direct Thrombin Inhibitors (DTIs) are anticoagulants that bind directly to thrombin (Factor IIa), inhibiting its ability to convert fibrinogen into fibrin. They are classified based on their route of administration into parenteral and oral agents. **1. Why Dabigatran is the correct answer:** Dabigatran (specifically Dabigatran etexilate) is the only **oral** Direct Thrombin Inhibitor among the options. It is a prodrug and belongs to the class of Non-vitamin K antagonist Oral Anticoagulants (NOACs/DOACs). It is primarily used for stroke prevention in non-valvular atrial fibrillation and the treatment of DVT/PE. **2. Why the other options are incorrect:** * **Lepirudin & Bivalirudin:** These are recombinant derivatives of hirudin (found in leech saliva). They are **parenteral** (IV) bivalent DTIs, meaning they bind to both the active site and the exosite of thrombin. * **Argatroban:** This is a synthetic small molecule and a **parenteral** (IV) univalent DTI, binding only to the active site of thrombin. It is the preferred agent for patients with Heparin-Induced Thrombocytopenia (HIT) who also have hepatic impairment (though it is primarily metabolized by the liver, unlike Lepirudin which is renal). **High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** The specific reversal agent for Dabigatran is **Idarucizumab** (a monoclonal antibody fragment). * **Monitoring:** Unlike Heparin (aPTT) or Warfarin (PT/INR), DTIs generally do not require routine monitoring. However, if needed, **Ecarin Clotting Time (ECT)** is the most sensitive test for DTIs. * **Drug of Choice:** Argatroban and Bivalirudin are the drugs of choice for managing **Heparin-Induced Thrombocytopenia (HIT)**.

Q: Which of the following drugs does not act on the P2Y12 receptor?

Dipyridamole. ### Explanation The question asks to identify the drug that does not belong to the **P2Y12 receptor antagonist** class. **1. Why Dipyridamole is the Correct Answer:** Dipyridamole is a **Phosphodiesterase (PDE) inhibitor**. It works by inhibiting the enzyme phosphodiesterase, which normally breaks down cyclic AMP (cAMP) [1]. By increasing intracellular cAMP levels in platelets, it inhibits platelet aggregation [1]. It also inhibits the cellular uptake of adenosine [1]. It does not interact with the P2Y12 ADP receptor. **2. Why the Other Options are Incorrect:** * **Ticlopidine, Clopidogrel, and Prasugrel** are all **Thienopyridines**. These are prodrugs that undergo hepatic metabolism to form active metabolites which **irreversibly** bind to and block the **P2Y12 subtype of ADP receptors** on the platelet surface [2], [3], [4]. This prevents the activation of the GPIIb/IIIa receptor complex, thereby inhibiting platelet aggregation [5]. **3. NEET-PG High-Yield Pearls:** * **P2Y12 Inhibitors Classification:** * *Irreversible (Thienopyridines):* Ticlopidine, Clopidogrel, Prasugrel [4]. * *Reversible (Non-thienopyridines):* **Ticagrelor** (oral), **Cangrelor** (IV) [3], [4]. * **Clopidogrel:** Requires activation by **CYP2C19**. Genetic polymorphism or concurrent use of Proton Pump Inhibitors (like **Omeprazole**) can reduce its efficacy [3]. * **Prasugrel:** More potent than clopidogrel but contraindicated in patients with a history of **Stroke or TIA** due to increased bleeding risk. * **Ticlopidine:** Rarely used now due to severe side effects like **Neutropenia** and Thrombotic Thrombocytopenic Purpura (TTP) [2]. * **Dipyridamole Clinical Use:** Often used in combination with Aspirin for stroke prophylaxis or used in **Pharmacological Stress Testing** (due to its coronary vasodilator properties—"Coronary Steal Phenomenon") [1].

Question 1

What is the latest oral direct thrombin inhibitor?

Accepted Answer

Dabigatran

Answer

Ximelagatran

Answer

Indraparinux

Answer

Fondaparinux

Question 2

Which of the following antiplatelet drugs is a P2Y12 receptor blocker not affected by CYP2C19 polymorphism?

Accepted Answer

Prasugrel

Answer

Clopidogrel

Answer

Eptifibatide

Answer

Dipyridamole

Question 3

Ferrous sulfate is a hydrated salt containing what percentage of Iron?

Accepted Answer

20%

Answer

25%

Answer

30%

Answer

35%

Question 4

What is the mode of action of warfarin?

Accepted Answer

Vitamin K antagonist

Answer

Factor Xa inhibitor

Answer

Activates antithrombin III

Answer

Activates factor IX

Question 5

Arrange the following drugs in decreasing order of their antiplatelet potency: Clopidogrel, Prasugrel, Aspirin, Abciximab?

Accepted Answer

Abciximab > Prasugrel > Clopidogrel > Aspirin

Answer

Prasugrel > Abciximab > Aspirin > Clopidogrel

Answer

Aspirin > Abciximab > Clopidogrel > Prasugrel

Answer

Clopidogrel > Abciximab > Aspirin > Prasugrel

Question 6

Low molecular weight heparin therapy is associated with all of the following except:

Accepted Answer

High biological interaction to plasma proteins

Answer

Less chances of bleeding

Answer

Single dose per day

Answer

Easy filterability by glomerular capillaries

Question 7

Warfarin therapy during the first trimester of pregnancy can lead to which of the following problems?

Accepted Answer

Chondrodysplasia punctata

Answer

Fetal optic atrophy

Answer

Mental retardation

Answer

None of the above

Question 8

Which of the following statements about erythropoietin is FALSE?

Accepted Answer

It results in a decrease in reticulocyte count

Answer

It is used for the treatment of anemia due to chronic renal failure

Answer

It decreases the requirement for blood transfusions

Answer

It can cause hypertension

Question 9

All of the following are parenteral Direct Thrombin Inhibitors except?

Accepted Answer

Dabigatran

Answer

Lepirudin

Answer

Bivalirudin

Answer

Argatroban

Question 10

Which of the following drugs does not act on the P2Y12 receptor?

Accepted Answer

Dipyridamole

Answer

Ticlopidine

Answer

Clopidogrel

Answer

Prasugrel

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?